Trials / Unknown
UnknownNCT03054545
Iguratimod as Treatment for Refractory Lupus Nephritis
Evaluation of Clinical Efficacy and Immunologic Response After Iguratimod Therapy in Refractory Lupus Nephritis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy and safety of a novel chemical synthetic agent iguratimod as treatment of refractory lupus nephritis. All subjects should have at least one failed immunosuppressive treatment and suffer active nephritis at the screening stage. The study period is 52 week. All the subject will receive therapy of iguratimod combined with steroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iguratimod | Iguratimod 25mg twice a day, oral administrated. |
Timeline
- Start date
- 2017-05-08
- Primary completion
- 2018-05-08
- Completion
- 2019-04-30
- First posted
- 2017-02-15
- Last updated
- 2017-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03054545. Inclusion in this directory is not an endorsement.